[1]CurrentPatentAssignee:DESIGNTHERAPEUTICS-WO2021/158707,2021,A1Locationinpatent:Paragraph00844;00848;00849;00850;001271;001277;001278
Title: The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Journal: Oncotarget 20170131
Title: Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
Journal: International journal of cancer 20170101
Title: OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.
Journal: Oncotarget 20161220
Title: Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
Journal: Oncotarget 20161129
Title: OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Journal: International journal of cancer 20161101
Title: Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Journal: Oncotarget 20160906
Title: Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Journal: The Lancet. Haematology 20160401
Title: Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
Journal: Clinical pharmacokinetics 20160301
Title: The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb.
Journal: Scientific reports 20160101
Title: BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Journal: Oncotarget 20150710
Title: Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
Journal: Chemistry & biology 20150618
Title: The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20150401
Title: Compendium of aberrant DNA methylation and histone modifications in cancer.
Journal: Biochemical and biophysical research communications 20141205
Title: Targeting bromodomains: epigenetic readers of lysine acetylation.
Journal: Nature reviews. Drug discovery 20140501
Title: Targeting epigenetic readers in cancer.
Journal: The New England journal of medicine 20121101
Title: J. Kay Noel, et al. Abstract C244: Development of the BET bromodomain inhibitor OTX015. Mol Cancer Ther November 2013 12; C244.
Title: Marie-Magdelaine Coudé, et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget. 2015 Jul 10; 6(19): 17698–17712.
Title: Lu P, et al. The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb. Sci Rep. 2016 Apr 12;6:24100
Title: Vázquez R, et al. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with RAD001. Oncotarget. 2017 Jan 31;8(5):7598-7613.
